Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Anaptys Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the rejection of the biotech's stomach disorder drug last year. The FDA has ...

Vanda Pharmaceuticals (NASDAQ:VNDA) is alleging that members of the U.S. FDA "have committed to delay" its request for a hearing to discuss the agency's issuing of a Complete Response Letter in ...

WASHINGTON, April 23, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced that FDA bureaucrats have committed to delay Vanda's request for a hearing on the ...

In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on AnaptysBio (ANAB – Research Report), with a price target of $51.00. The company’s shares closed yesterday ...

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company with a market capitalization of $252.51 million and impressive gross profit margins of 94.31%, reported that the ...

Currently, the analyst consensus on AnaptysBio is a Strong Buy with an average price target of $43.00.

At least that is what Vanda Research reckons. The firm’s Retail Capitulation index — which it says captures not just net purchases but also purchases’ breadth, sentiment, leverage ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company. In a statement, the company says the FDA's ...